1416984-76-3

Basic information

• Product Name: 1-Boc-4-aMinoMethyl-4-hydroxyMethylpiperidine
• Synonyms: 1-Boc-4-aMinoMethyl-4-hydroxyMethylpiperidine;tert-butyl 4-(aminomethyl)-4-(hydroxymethyl)piperidine-1-carboxylate
• CAS NO: 1416984-76-3
• Molecular Formula: C₁₂H₂₄N₂O₃
• Molecular Weight: 244.33056
• Mol File: 1416984-76-3.mol

Chemical Properties

• Boiling Point: 355.2±7.0 °C(Predicted)
• Appearance: /
• Density: 1.078±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.94±0.10(Predicted)
• CAS DataBase Reference: 1-Boc-4-aMinoMethyl-4-hydroxyMethylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-aMinoMethyl-4-hydroxyMethylpiperidine(1416984-76-3)
• EPA Substance Registry System: 1-Boc-4-aMinoMethyl-4-hydroxyMethylpiperidine(1416984-76-3)

Safety Data

• Hazardous Substances Data: 1416984-76-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Boc-4-aMinoMethyl-4-hydroxyMethylpiperidine is used as a key intermediate for the synthesis of various drugs and biologically active molecules, contributing to the development of new therapeutic agents.
Used in Organic Synthesis:
1-Boc-4-aMinoMethyl-4-hydroxyMethylpiperidine is used as a building block in organic synthesis, enabling the creation of a wide range of organic compounds due to its unique structure and reactivity.
Safety and Handling:
1-Boc-4-aMinoMethyl-4-hydroxyMethylpiperidine is typically handled and stored according to standard chemical safety procedures to mitigate potential health and environmental hazards. Its use is regulated to ensure safe application in various industries.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 4395-98-6 4-cyanopiperidine 
• 614730-96-0 tert-butyl 4-cyano-4-(hydroxymethyl) piperidine-1-carboxylate 
• 1016258-66-4 1-(tert-butyl) 4-ethyl 4-cyanopiperidine-1,4-dicarboxylate 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 

Downstream Products

• 1416984-93-4 N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichlorobenzamide 
• 1416984-84-3 tert-butyl 4-((3,5-dichlorobenzamido)methyl)-4-(hydroxymethyl)piperidine-1-carboxylate 
• 1416984-94-5 3,5-dichloro-N-((4-(hydroxymethyl)piperidin-4-yl)methyl)benzamide hydrochloride 

Relevant articles and documents

QUINAZOLINE COMPOUND FOR EGFR INHIBITION

Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4- piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor

The T-type calcium channel inhibitor Mibefradil was reported to protect the heart from atrial remodeling, a key process involved in the development of atrial fibrillation and arrhythmias. Mibefradil is not a selective T-type calcium channel inhibitor and also affects the function of different ion channels. Our aim was to develop a selective T-type calcium channel inhibitor to validate the importance of T-type-related pharmacology in atrial fibrillation. Structural optimisation of a previously disclosed hit series focussed on minimising exposure to the central nervous system and improving pharmacokinetic properties, while maintain adequate potency and selectivity. This resulted in the design of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4- piperidyl]methyl]-3,5-dichloro-benzamide, a novel, selective, peripherally restricted chemical probe to verify the role of T-type calcium channel inhibition on atrial fibrillation protection.